quanTB

{Photo credit: Mark Tuschman.}Photo credit: Mark Tuschman.

This post originally appeared on the SIAPS website.

After decades of relying on old medicines, new drugs designed specifically for the treatment of tuberculosis (TB) are finally on the market. While these medicines represent a major advancement in the fight against TB, ensuring equitable access for patients is still an enormous challenge. At the 45th Union World Conference on Lung Health, the US Agency for International Development (USAID)-funded Systems for Improved Access to Pharmaceuticals and Services (SIAPS) program, led by Management Sciences for Health (MSH), collaborated with the Stop TB Partnership Global Drug Facility (GDF) to host a full-day workshop addressing common hurdles to treatment access, as well as available solutions.

The SIAPS program focused on three common challenges in medicines availability: quantification, public-private mixes, and medicines safety.

 {Photo credit: Mark Tuschman.}A pharmacy in Kenya.Photo credit: Mark Tuschman.

Guaranteeing that patients have uninterrupted access to anti-tuberculosis (TB) treatment begins with national TB programs (NTP) making complex calculations about how many cases to expect in the future.  Vigilant stock management, accurate number of cases started on each type of treatment along with forecasting the expected number of patients that will be enrolled on treatment, are vital to ensure that medicines are available to all patients who need them.

To promote a systems-strengthening approach to TB medicines management, the US Agency for International Development (USAID)-funded Systems for Improved Access to Pharmaceuticals and Services (SIAPS) program developed QuanTB—a downloadable, desktop tool that transforms intricate calculations into a user-friendly dashboard displaying key quantification and supply planning information.

Printer Friendly Version
Subscribe to RSS - quanTB